# Oral GW766944 (Oral CCR3 Antagonist)

> **NCT01160224** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GW766944
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01160224
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-08
- **Primary completion:** 2011-08-29
- **Final completion:** 2011-08-29
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160224, "Oral GW766944 (Oral CCR3 Antagonist)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01160224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*